Topics

Articles

Biosimilars market experiences massive growth, but regulatory and adoption challenges remain.

Getting the Lay of the Land After a Banner Year for Biosimilars

A USC study discovers that an increasing share of both generic and brand-name meds are being excluded from approval. 

Taking a Closer Look at Medicare Part D’s Rising Drug Coverage Restrictions

Videos

In an interview with Pharma Commerce Associate Editor Don Tracy, Corey Ford, VP, Reimbursement & Policy Insights, Cencora, offers his thoughts on where the Inflation Reduction Act will be five to 10 years from now. 

Cencora's Corey Ford Discusses the Future of the Inflation Reduction Act

An MDVIP study reports that 61% of people feel hassled by the current structure. 


Survey Reveals Americans’ Frustrations With the Healthcare System

In an interview with Pharma Commerce Associate Editor Don Tracy, Corey Ford, VP, Reimbursement, Policy Insights, Cencora, provides a look at his recent webinar focused on the implications of the Inflation Reduction Act. 

Cencora VP of Reimbursement & Policy Insights Discusses Implications of the Inflation Reduction Act

A cohort study explores the association of Medicare Advantage enrollment with post-acute care use, along with patient outcomes among retired state employees.

The Perks of Medicare Advantage Versus Traditional Medicare

A cross-sectional study investigates how this supply chain link helps increase Medicare Part D spending on self-administered specialty drugs.

Identifying Trends Surrounding the Use of In-House Pharmacies for High-Cost Drugs

A cohort study investigates how a change in clinical guidelines, an expanded label, and reduction in drug prices can impact the use of PCSK9 inhibitors as a treatment for atherosclerotic cardiovascular disease.

Analyzing PCSK9 Inhibitor Use in Adults With Cardiovascular Disease

A trial set out to determine whether empagliflozin can help prevent hospitalizations and extend life for patients with heart failure, while not hurting the US payers’ pockets. 

Calculating the Cost-Effectiveness of Empagliflozin in Patients Experiencing Heart Failure 

The lack of transparency in the pharmaceutical industry further exacerbates the challenges faced by consumers. 

Market Access and Pricing